Great West Life Assurance Co. Can Has $2.65 Million Holdings in Intellia Therapeutics Inc (NTLA)

Great West Life Assurance Co. Can raised its stake in shares of Intellia Therapeutics Inc (NASDAQ:NTLA) by 2.5% in the second quarter, HoldingsChannel.com reports. The fund owned 97,031 shares of the company’s stock after acquiring an additional 2,395 shares during the period. Great West Life Assurance Co. Can’s holdings in Intellia Therapeutics were worth $2,652,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently modified their holdings of NTLA. Legal & General Group Plc raised its holdings in shares of Intellia Therapeutics by 75.4% in the second quarter. Legal & General Group Plc now owns 5,427 shares of the company’s stock valued at $149,000 after buying an additional 2,333 shares during the last quarter. D.A. Davidson & CO. raised its holdings in shares of Intellia Therapeutics by 14.2% in the first quarter. D.A. Davidson & CO. now owns 19,219 shares of the company’s stock valued at $405,000 after buying an additional 2,395 shares during the last quarter. TRUE Private Wealth Advisors raised its holdings in shares of Intellia Therapeutics by 23.5% in the second quarter. TRUE Private Wealth Advisors now owns 13,296 shares of the company’s stock valued at $363,000 after buying an additional 2,533 shares during the last quarter. New York State Common Retirement Fund raised its holdings in shares of Intellia Therapeutics by 12.8% in the first quarter. New York State Common Retirement Fund now owns 25,990 shares of the company’s stock valued at $548,000 after buying an additional 2,950 shares during the last quarter. Finally, Swiss National Bank raised its holdings in shares of Intellia Therapeutics by 11.3% in the second quarter. Swiss National Bank now owns 42,500 shares of the company’s stock valued at $1,163,000 after buying an additional 4,300 shares during the last quarter. 66.52% of the stock is owned by institutional investors.

Intellia Therapeutics stock opened at $31.05 on Friday. The stock has a market capitalization of $1.31 billion, a P/E ratio of -16.52 and a beta of 3.09. Intellia Therapeutics Inc has a 12-month low of $16.33 and a 12-month high of $35.99.

Intellia Therapeutics (NASDAQ:NTLA) last announced its quarterly earnings data on Wednesday, August 1st. The company reported ($0.52) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.55) by $0.03. The firm had revenue of $7.68 million during the quarter, compared to analyst estimates of $6.39 million. Intellia Therapeutics had a negative return on equity of 31.54% and a negative net margin of 284.56%. The company’s revenue was up 30.2% on a year-over-year basis. During the same period last year, the company earned ($0.45) earnings per share. research analysts predict that Intellia Therapeutics Inc will post -1.97 EPS for the current fiscal year.

A number of research firms recently issued reports on NTLA. BidaskClub raised Intellia Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday. Zacks Investment Research raised Intellia Therapeutics from a “hold” rating to a “buy” rating and set a $30.00 price target for the company in a report on Saturday, August 4th. Chardan Capital reaffirmed a “buy” rating and issued a $57.50 price target on shares of Intellia Therapeutics in a report on Friday, August 24th. Finally, ValuEngine raised Intellia Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, June 2nd. Three research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $39.50.

In related news, Director Jean Francois Formela sold 6,686 shares of Intellia Therapeutics stock in a transaction dated Monday, July 16th. The stock was sold at an average price of $31.17, for a total value of $208,402.62. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 12.80% of the stock is owned by company insiders.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism programs.

See Also: How Do You Calculate Return on Equity (ROE)?

Want to see what other hedge funds are holding NTLA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intellia Therapeutics Inc (NASDAQ:NTLA).

Institutional Ownership by Quarter for Intellia Therapeutics (NASDAQ:NTLA)

Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply